Coverage of "Rinvoq" on Cryptosearcher: the stories and the context behind them.
AbbVie’s shares rose after EU approval of RINVOQ for severe alopecia areata, expanding the drug’s reach in immune-related diseases and offering new options for hair loss patients.
July 29, 2026
